Skip to main content
Signal8
Launch Terminal

GERON CORP (GERN)

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Geron Corporation logo

Geron Corporation

NASDAQ:GERNHealthcare
-5.47%$0.8944
AH$0.8901-0.48%vs close
Mkt Cap$574.63M
Float626.73M
O/S642.47M
Vol
$ Vol
RVOL
Inst Own74.2%
SI11.9%
Earnings
Dilution
Geron Corporation logoNASDAQ:GERN$0.8944-5.47%
Upcoming Catalysts
  • imetelstatREADOUT
    Cash runway at this date: 23mo
    Oct 28, 20265d ago8-K
Phase Distribution
16 lead-sponsored trials·3 active·12 completed
Phase 17
Phase 26
Phase 2/31
Phase 31
Not applicable1
(6 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

    Imetelstat, Best Available Therapy (BAT)

    Myelofibrosis

    Enrollment
    327
    Start
    Apr 2021
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2028est.
    NCT04576156
  • Phase 2/3
    Active, not recruiting

    Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Imetelstat Sodium, Placebo

    Myelodysplastic Syndromes

    Enrollment
    289
    Start
    Jan 2016
    Primary Completion
    Oct 2023
    Completion
    Oct 2026est.
    NCT02598661
  • Phase 2
    Completed

    Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

    imetelstat, Bevacizumab

    Non-small Cell Lung Cancer

    Enrollment
    116
    Start
    May 2010
    Primary Completion
    Sep 2013
    Completion
    Sep 2013
    NCT01137968
  • Phase 2
    Completed

    Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

    Imetelstat (7.5 mg/kg), lenalidomide standard of care

    Multiple Myeloma

    Enrollment
    13
    Start
    Nov 2010
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT01242930
  • Phase 2
    Completed

    Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

    Imetelstat

    Essential Thrombocythemia, Polycythemia Vera

    Enrollment
    20
    Start
    Dec 2010
    Primary Completion
    Oct 2013
    Completion
    Apr 2015
    NCT01243073
  • Phase 2
    Completed

    Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

    Imetelstat sodium, Bevacizumab

    Locally Recurrent or Metastatic Breast Cancer

    Enrollment
    166
    Start
    Nov 2010
    Primary Completion
    Oct 2012
    Completion
    Dec 2012
    NCT01256762
  • Phase 2
    Completed

    Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

    Imetelstat

    Primary Myelofibrosis, Secondary Myelofibrosis +1

    Enrollment
    80
    Start
    Oct 2012
    Primary Completion
    May 2018
    Completion
    May 2018
    NCT01731951
  • Phase 2
    Completed

    Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

    Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg

    Myelofibrosis

    Enrollment
    107
    Start
    Aug 2015
    Primary Completion
    Apr 2018
    Completion
    Feb 2020
    NCT02426086
  • Phase 1
    Completed

    Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

    GRN163L

    Chronic Lymphoproliferative Diseases

    Enrollment
    48
    Start
    Jul 2005
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT00124189
  • Phase 1
    Completed

    Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

    Imetelstat Sodium (GRN163L)

    Solid Tumor Malignancies

    Enrollment
    85
    Start
    Mar 2006
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT00310895
  • Phase 1
    Completed

    Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

    Imetelstat Sodium (GRN163L)

    Lung Cancer

    Enrollment
    27
    Start
    Jul 2007
    Primary Completion
    Apr 2011
    Completion
    Apr 2011
    NCT00510445
  • Phase 1
    Completed

    Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

    Imetelstat Sodium (GRN163L)

    Multiple Myeloma

    Enrollment
    20
    Start
    Nov 2007
    Primary Completion
    Jul 2011
    Completion
    Jul 2011
    NCT00594126
  • Phase 1
    Completed

    Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

    Imetelstat Sodium (GRN163L)

    Multiple Myeloma

    Enrollment
    40
    Start
    Jul 2008
    Primary Completion
    Oct 2011
    Completion
    Oct 2011
    NCT00718601
  • Phase 1
    Completed

    A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

    GRN163L

    Breast Cancer

    Enrollment
    24
    Start
    Jul 2008
    Primary Completion
    Sep 2011
    Completion
    Mar 2012
    NCT00732056
  • Phase 1
    Active, not recruiting

    A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

    Imetelstat sodium, Ruxolitinib

    Myelofibrosis

    Enrollment
    30
    Start
    May 2022
    Primary Completion
    Feb 2027est.
    Completion
    Aug 2028est.
    NCT05371964
  • Expanded access
    Approved for marketing

    Expanded Access for Treatment With Imetelstat

    Imetelstat

    Myelodysplastic Syndromes

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05937568
Search ClinicalTrials.gov for “Geron”